Positive Airway Pressure Use Tied to Lower Cardiovascular Events
By Lori Solomon HealthDay Reporter
TUESDAY, Sept. 17, 2024 -- Positive airway pressure (PAP) utilization is associated with lower all-cause mortality and major adverse cardiovascular event (MACE) incidence in older adults with obstructive sleep apnea (OSA), according to a study published online Sept. 11 in JAMA Network Open.
Diego R. Mazzotti, Ph.D., from the University of Kansas Medical Center in Kansas City, and colleagues sought to determine whether PAP initiation and utilization are associated with lower mortality and incidence of MACE among older U.S. adults with OSA. The analysis included 888,835 Medicare beneficiaries with two or more distinct OSA claims identified from multistate, statewide, multiyear Medicare fee-for-service claims data (2011 to 2020) with follow-up until death or censoring through 2020.
The researchers found that during a median follow-up of 3.1 years, those with evidence of PAP initiation (32.6 percent) had significantly lower all-cause mortality (hazard ratio, 0.53) and MACE incidence risk (hazard ratio, 0.90). There was a progressive association between higher quartiles of annual PAP claims and lower mortality and MACE incidence risk.
"These results might inform future trials assessing the importance of obstructive sleep apnea therapies toward minimizing cardiovascular risk and mortality in older adults," the authors write.
One author disclosed being a cofounder of Hypnoscure.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
Personality Tied to Cardiovascular Disease Risk With Type 2 Diabetes
TUESDAY, Sept. 17, 2024 -- Personality traits can influence cardiovascular disease (CVD) risk with type 2 diabetes mellitus (T2DM), according to a study published online Sept. 10...
Before and After Market Testing Rare for Cardiovascular Devices With Class I Recalls
TUESDAY, Sept. 17, 2024 -- Cardiovascular devices with Class I recalls appear to be rarely subjected to premarket or postmarket testing, according to a study published online...
Gestational Hypertension Tied to Higher Later Risk for Cardiovascular Disease
MONDAY, Sept. 16, 2024 -- A self-reported history of gestational hypertension is associated with cardiovascular disease (CVD) in postmenopausal women, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.